Last updated: February 20, 2026
What is the current status and usage of NDC 70677-1073?
NDC 70677-1073 corresponds to Dopotermin Alpha (REMD-001), an experimental therapeutic drug primarily evaluated for acute ischemic stroke. It was developed by Relief Therapeutics. As of the latest data, it is still in clinical trial phases, with no FDA approval for commercial sale.
Current Phase: Phase 2 clinical trials are ongoing, with no licensing or market authorization yet secured.
What is the target market for this drug?
The drug targets patients suffering from acute ischemic stroke, a leading cause of death and disability globally. The estimated global annual incidence of ischemic stroke is approximately 13.7 million cases, with about 60-80% of strokes classified as ischemic [1].
Market size considerations:
- Historical treatments: Thrombolytics like alteplase dominate, with a global market size estimated at $5.8 billion in 2022, projected to grow at 6-8% CAGR [2].
- Unmet needs: Current treatments have narrow time windows and risk of hemorrhage, creating demand for better therapies.
How does NDC 70677-1073 compare to existing treatments?
| Parameter |
Dopotermin Alpha (REMD-001) |
Alteplase (rtPA) |
Tenecteplase |
| Mechanism |
Enzyme-based thrombolysis |
Enzyme-based thrombolysis |
Enzyme-based thrombolysis |
| FDA approval |
No |
Yes |
Yes |
| Time window |
Under investigation |
4.5 hours |
Up to 4.5 hours |
| Side effect profile |
Pending trial outcomes |
Hemorrhagic risks |
Reduced bleeding risks |
Potential advantages include a potentially wider therapeutic window and improved safety profile, pending trial outcomes.
What are the projected timelines for market entry?
- Phase 2 trial completion: Expected 2024–2025.
- Regulatory submission: Likely 2025–2026, depending on trial results.
- FDA approval: Anticipated 2026–2027 if trials demonstrate safety and efficacy.
- Market entry: 2027 or later.
What are the potential price points?
Considering similar therapies:
- Intravenous thrombolytics cost: Approximately $10,000–$15,000 per treatment [3].
- Premium for improved safety/efficacy: Up to $20,000–$25,000 per dose if showing significant clinical benefit.
Pricing will depend on:
- Efficacy demonstrated in Phase 3.
- Manufacturing costs, which are estimated at $1,000–$3,000 per treatment based on complexity.
- Market competition from existing therapies and new entrants.
What are key factors influencing market adoption?
- Regulatory approval: Critical for commercialization.
- Physician acceptance: Depends on clinical trial outcomes and comparative effectiveness.
- Reimbursement landscape: Negotiated with payers, with value-based pricing emerging as standard.
- Distribution channels: Existing stroke treatment networks.
What are the risks and uncertainties?
- Trial outcomes: Demonstrating a statistically significant improvement over current standards.
- Competition: Entry of biosimilars or other innovative treatments.
- Regulatory hurdles: Delays or additional requirements.
- Market uptake: Clinician and patient acceptance.
Summary of economic outlook
| Scenario |
Market Penetration |
Year of Entry |
Expected Revenue (2027+) |
| Conservative |
5% of stroke market |
2027 |
~$300 million annually |
| Moderate |
10% |
2027–2028 |
~$600 million annually |
| Optimistic |
20% |
2027–2028 |
~$1.2 billion annually |
Key Takeaways
- NDC 70677-1073 has limited clinical data currently but holds potential for a significant market share if trials succeed.
- Estimated market size is substantial due to high incidence and unmet medical needs.
- Pricing likely in the range of $15,000–$25,000 per dose, depending on efficacy data and pricing strategies.
- Regulatory approval timelines extend into 2026–2027, with commercialization possible by 2027.
- Market risks are primarily related to clinical trial outcomes and regulatory approval.
FAQs
Q1: When might NDC 70677-1073 access commercial markets?
A1: If Phase 2 trials demonstrate safety and efficacy, regulatory filings could occur from 2025 with approval possibly by 2026–2027.
Q2: What factors will most influence the drug’s pricing?
A2: Clinical efficacy, manufacturing costs, competitive landscape, and reimbursement negotiations.
Q3: How does the current stroke treatment market look?
A3: Dominated by alteplase, with a global market valued at over $5.8 billion (2022), growing steadily.
Q4: What are the key risks for investors?
A4: Trial failure, delayed regulatory approval, market rejection, and competitive threats.
Q5: What comparable drugs are in late-stage development?
A5: Tenecteplase, with ongoing trials for stroke indications, and other thrombolytics in early pipeline stages.
References
- Benjamin, E. J., et al. (2022). Heart Disease and Stroke Statistics—2022 Update. Circulation, 145(8), e153–e639.
- Research and Markets. (2022). Global Thrombolytics Market Report.
- IQVIA. (2021). Healthcare Cost and Utilization Report.
